NCT01656031View on ClinicalTrials.gov

A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Leukemia
Interventions
DRUG

clofarabine

DRUG

cytarabine

Trial Locations (1)

27157-1096

Wake Forest University Comprehensive Cancer Center, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT01656031 - A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter